Blog
RSS FeedPosted by Michael Wonder on 26 Jun 2023
New report from The King’s Fund shows the UK underperforming on treatable health conditions, says the ABPI
26 June 2023 - The King’s Fund today published their independent report commissioned by the ABPI comparing the NHS to other ...
Posted by Michael Wonder on 05 Sep 2020
International reference pricing: discounts down under far surpass U.S. drug price concessions
1 September 2020 - At 30,000 feet, the view of Australia’s healthcare system does not look too different from our own ...
Posted by Michael Wonder on 16 Aug 2020
Direct or indirect comparison: reliance on innovative drug data key to engaging data protection
15 August 2020 - The Federal Court recently issued its decision in Natco v Canada (Minister of Health), 2020 FC 788, ...
Posted by Michael Wonder on 19 Jul 2020
PBAC asks Roche for another comparison for Tecentriq
20 July 2020 - The submission requested a PBS (Section 100) listing for atezolizumab for use in combination with taxane chemotherapy ...
Posted by Michael Wonder on 12 May 2020
A comparison of the EQ-5D-3L and EQ-5D-5L
12 May 2020 - Previous studies have found the EQ-5D-5L to have superior measurement properties but no study has compared ...
Posted by Michael Wonder on 30 Nov 2019
Performance of UK National Health Service compared with other high income countries: observational study
27 November 2019 - The UK’s spending on health care has been constrained for some time, with slow growth in spending ...
Posted by Michael Wonder on 25 Nov 2019
Medicine prices in Australia among the cheapest in the world, research shows
25 November 2019 - If you take medication for several health issues, you may be surprised to find out Australia has ...
Posted by Michael Wonder on 12 Aug 2019
New Zealand's access to funded medicines 'well behind the rest of the world'
12 August 2019 - New Zealand has the worst access to funded modern medicines of 20 OECD countries, a report ...
Posted by Michael Wonder on 14 Jul 2019
Bev takes 14 pills a day. She's far from alone.
15 July 2019 - She is among the more than one-in-three Australians aged over 70 who take five or more different ...
Posted by Michael Wonder on 17 Jun 2019
Population adjustment methods for indirect comparisons: A review of NICE Technology Appraisals
13 June 2019 - Indirect comparisons via a common comparator (anchored comparisons) are commonly used in health technology assessment. However, ...
Posted by Michael Wonder on 08 Feb 2019
What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries.
7 February 2019 - Decisions on the reimbursement of the same cancer drugs are different across European countries, but empirical work ...
Posted by Michael Wonder on 06 Feb 2019
Comparing PHARMAC's outcomes with those of Australia
7 February 2019 - New Zealand's Prime Minister Jacinda Ahern's claim that is unfair to compare PHARMAC's outcomes with those ...
Posted by Michael Wonder on 05 Feb 2019
Jacinda Ardern: not fair to compare PHARMAC with Australia's system
5 February 2019 - Jacinda Ardern told The AM Show New Zealand's drug buying agency has "been pointed to as being ...
Posted by Michael Wonder on 12 Nov 2018
PBAC shows no propensity to support Amgen's innovative method of analysis
12 November 2018 - Amgen's recent submission for blinatumomab (Blincyto) treatment of patients with B-cell precursor acute lymphoblastic leukaemia in haematological ...
Posted by Michael Wonder on 09 Oct 2018
Outdated public funding model failing New Zealand patients
9 October 2018 - Publicly funded modern medicines are out of reach for many patients in New Zealand according to ...